FYI: These 20 Memorial Day Mattress Sales Have Already Started
Memorial Day weekend is still a few weeks away, but as usual, many retailers are rolling out enticing early offers. If you've been waiting for a good Memorial Day mattress sale, some of our sleep editors' favorite beds—including the Helix Midnight Luxe (our pick for the best mattress overall) and the Nectar Premier (our favorite memory foam mattress)—are already discounted by up to 58%.
Check out these early Memorial Day mattress sales to save up to 58% on a brand new bed. ILLUSTRATION: FORBES / PHOTO: RETAILER
If you can wait, we'll likely see mattress prices drop even lower as the holiday weekend draws closer. Waiting until Memorial Day weekend to shop could save you an additional 5 to 10% on a new bed. But if you want one ASAP, the current selection of deals is pretty solid. Here are the best early Memorial Day mattress sales we've spotted so far, including deals on eight models our editors have tested firsthand.
The lofty and supportive Helix Midnight Luxe has held its spot as our favorite mattress overall for over a year. Our testers ranked the mattress highly across the board, particularly highlighting its pressure relief, edge support and plush pillow-top.
More Deal Information: Helix offered 30% off this mattress last Memorial Day, so it may be worth waiting for the additional drop if you want to save the most.
Both temperature and snoring can dramatically impact your quality of sleep. If you are (or sleep with) a snorer, this design is incredibly customizable and automatically adjust to you as you sleep. It's also made with temperature-regulating materials, like ceramic-infused foam, that are supposed to pull heat away as you sleep.
More Deal Information: This 30% discount is already one of the best prices we've seen for this best-selling smart mattress, including offers we saw last May.
Formerly the DreamCloud Premier Rest Hybrid, this bed was recently updated with a new name, but it still has all of the features that made it a top pick. Ideal for couples, back and side sleepers, the design truly excels at pressure relief. Its average rating was 9 out of 10, but several testers gave the mattress a full 10, describing the experience as 'sleeping on a cloud that has structure to it.'
More Deals Information: This discount matches the offer we saw last Memorial Day.
This newly updated mattress delivers ample pressure relief with deep contouring to your hips and shoulders. While you'll still feel more 'in' than 'on' your mattress, the Premier is more responsive than the average memory foam design (including its previous iteration), so you can easily change positions throughout the night.
More Deal Information: This discount has remained fairly steady for months now.
Hot sleepers may find some relief from this cooling Brooklyn Bedding mattress, which uses gel-infused memory foam to draw heat away from the body. The breathable hybrid design comes in three firmness levels and offers good edge support. As a hot sleeper herself, senior mattress and sleep editor Bridget Chapman wrote a dedicated review of the Aurora Luxe.
More Deals Information: Brooklyn Bedding typically offers a boosted 30% off over holiday weekends, so wait until Memorial Day if you want to save an extra 5%.
Supportive and cooling, the Leesa Sapira Chill an excellent hybrid design that can accommodate a variety of sleep styles. It also comes in three firmness levels, with one tester describing the medium-firm model as 'plush and airy but on the sturdier side of the scale.' We recommend the plush model for strict side sleepers and anyone with sensitive joints.
More Deals Information: Forbes Vetted readers can save an additional $50 on this model with code FORBES50.
MOST POPULAR
This hybrid innerspring mattress delivers excellent support, spinal alignment and pressure relief, making it our favorite mattress to help combat back pain. The bed also received a unanimous 10 out of 10 for edge support by our testers.
More Deals Information: Saatva often offers $300 off select models, so this is a nice opportunity to save a little extra.
The Plank Firm is one of the firmest mattresses we've ever tested. It has a flippable foam design that lets you choose between two firmness levels and it's one of few mattresses recommended by the American Chiropractic Association (ACA).
More Deals Information: This 25% off discount has been active for most of 2025. The brand offered 30% off for Memorial Day last year, so if you want the additional savings, it may be worth holding out.
When Is Memorial Day 2025?> When Is Memorial Day 2025?
Memorial Day 2025 falls on Monday, May 26. That said, we're already seeing some early Memorial Day offers that will likely run through the holiday weekend.
Is Memorial Day A Good Time To Buy A Mattress? > Is Memorial Day A Good Time To Buy A Mattress?
Holiday weekends are a great time to score a discounted mattress, Memorial Day included. Some retailers may wait until the weekend to drop the absolute best prices, but most are already offering great deals. We'll continue updating this list leading up to and throughout the holiday.
What's The Best Month For Mattress Sales?> What's The Best Month For Mattress Sales?
May is one of the best months to buy a mattress: We track prices year-round and have found that Memorial Day sales offer some of the lowest prices of the year—aside from the week after Thanksgiving.
September (during Labor Day weekend) and November (particularly Black Friday) are also good months to buy a mattress. However, if your current setup is causing your sleep to suffering now, you may want to replace your mattress sooner rather than later.
How Do I Get The Best Price On A New Mattress?> How Do I Get The Best Price On A New Mattress?
In addition to shopping during major holidays, another pro tip for saving on a mattress is to look for discounts on bundles. Some mattress brands offer special prices when you buy a bed frame and mattress together. You can also consider shopping for an older, but still well-rated, mattress. Many brands will discount last year's designs as newer models are released.
Which Holiday Is The Best Time To Buy A Mattress?> Which Holiday Is The Best Time To Buy A Mattress?
Historically, holidays like Presidents' Day, Memorial Day, July 4 and Labor Day bring out similar mattress discounts or around 20% to 50% off. However, Black Friday and Cyber Monday usually bring the absolute lowest prices of the year—you'll generally see most popular mattresses marked down by 35% or more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
35 minutes ago
- Yahoo
Christina Bohannan makes third run for Iowa's 1st Congressional District
Jun. 21—History shows that just because a candidate makes multiple attempts to win an election doesn't mean they can't eventually pull through. U.S. Rep. Mariannette Miller-Meeks lost a number of times to Dave Loebsack before winning Iowa's 1st Congressional District seat in a close 2020 election. Now her past Democratic challenger, Christina Bohannan, is attempting the same thing for the 2026 election cycle, provided she is the favorite in the primary. On June 17, Bohannan announced her campaign to take on Miller-Meeks once again. In a press release, her campaign said Bohannan nearly defeated Miller-Meeks in 2024 — less than 800 votes decided the election — and that the Democrat "outworked, outraised and outmatched her." Bohannan said, "Mariannette Miller-Meeks has had three terms in Congress — three chances to do right by the people of Iowa. Instead, she has taken over $4 million from corporate special interests and done nothing but vote their way. And she has put partisan politics over Iowans again and again. From cutting billions of dollars from Medicaid in the Trump Administration's One Big Beautiful Bill, to siding with DOGE's cuts to Social Security and enabling unelected, unaccountable billionaires like Elon Musk, Bohannan said the Republican congresswoman has forgotten about her constituents. "It's time someone put Iowa first," Bohannan said. Bohannan went on to say Miller-Meeks needs to explain "why she keeps putting Washington special interests first." The Democratic challenger claimed Miller-Meeks supported Trump's One Big Beautiful Bill, repeatedly voted for cost-increasing tariffs and is a member of the DOGE Caucus. Bohannan previously worked as an engineer and taught at the University of Iowa College of Law for 20 years. She also worked as an elected legislator for the Iowa House, defeating a 20-year incumbent in District 85. Bohannan is running for Congress because she believes in a government that works for the people. In May, another Democrat announced he would be running for Iowa's 1st Congressional District. Bob Krause, a former legislator who also tried running for U.S. Senate, announced his campaign with the slogan "Flip The House With Krause." Krause said Miller-Meeks votes "like Trump's rubber stamp." Travis Terrell, a Democrat from Johnson County, also announced his bid for Iowa's 1st Congressional District race. His campaign page on Facebook notes he is a working-class, New Deal Democrat fighting for healthcare, fair wages and a government that serves other working-class people and not billionaires. In addition to Miller-Meeks likely running for the seat, fellow Republican and former primary challenger David Pautsch announced in February that he would also be running for the seat. Pautsch touts himself as a MAGA Republican. He has been critical of Miller-Meeks, saying she is not conservative enough.
